|
|
 |
|
Viewing report
|
|
|
|
Atopic Dermatitis: Generic Erosion Leads to Stagnant Market
Decision Resources, Inc., June 2006, Pages: 16
Atopic dermatitis is one of the largest segments of the dermatology disease market in terms of patient population. However, sales in this market are relative small, primarily because of generics competition. Symptomatic treatment of atopic dermatitis relies primarily on the use of topical formulations (corticosteroids and immunosuppressants). Physicians consider current oral treatments to have limited value in the treatment of atopic dermatitis; antihistamines are the primary class of oral agents used.
One of the key issues in the development of new treatments for this disease is the development of more-effective formulations that provide better delivery of either new or established agents to the affected parts of the skin. This report provides an overview of atopic dermatitis, including its symptoms, pathophysiology, and prevalence in the seven major markets we cover. We discuss the currently available treatments for atopic dermatitis and the emerging agents for the treatment of this disease, and we provide an analysis of the market out to 2010, including the role of emerging agents and the increasing presence of specialist companies.
Business Implications
Although atopic dermatitis is one of the most significant dermatology markets in terms of prevalence, sales in this indication are relatively small, accounting for $375 million in the seven major markets in 2005. The United States and Japan account for most of the revenues in the atopic dermatitis market, respectively generating $184 million and $102 million of the 2005 revenues in this market segment. The treatment of atopic dermatitis currently relies predominantly on three classes of agent: topical corticosteroids, topical immunosuppressants, and oral antihistamines, with the last principally used in Japan. Both the topical corticosteroid and antihistamine markets are highly fragmented, with a significant number of generic agents available.
The two topical immunosuppressants pimecrolimus (Novartis’s Elidel) and tacrolimus (Astellas's Protopic) are the leading branded products in this segment and, until 2005, were the market’s only significant growth drivers. They produced combined revenues of $133 million for the treatment of atopic dermatitis in 2005, with U.S. sales declining sharply in the past year because of the FDA’s imposition of a black box warning because of safety concerns. The impact of these safety concerns and the lack of innovative new therapeutics in latestage development for the treatment of atopic dermatitis will lead to a period of negligible revenue growth.
Only after 2010, if some of the new approaches in clinical development prove successful, is significant growth in the value of this market segment likely to occur. In the absence of such developments, revenues from this market segment will decline slightly.
Customers who bought this item also bought
Stakeholder Opinion: Atopic Dermatitis - A High Level of Unmet Need Creates Market Opportunities
Pipeline and Commercial Perspectives: Psoriasis and Atopic Dermatitis - Reimbursement the key as biologics and TIMs transform disease markets
Dermatology Seborrheic Dermatitis
The Dermatology Market Outlook to 2013: Competitive Landscape, Pipeline Analysis and Growth Opportunities
The Dermatology Market Outlook to 2011
Update on Dermatology Market
U.S. Topical Hemostats and Tissue Sealants Markets
Systemic Lupus Erythematosus Imprecise Segmentation Complicates Treatment Algorithms
Treating COPD Comorbidities: A Market Opportunity for Systemic Anti-Inflammatory Agents?
Cystic Fibrosis: Will New Agents Emerge as First-Line Therapies?
Does the Treatment of Huntingtons Disease Represent a Commercial Opportunity?
Stakeholder Insight: Inflammatory Bowel Disease - Debate over early aggressive treatment continues
|
|
|
|
